Investor Relations
Latest News and Press Releases
September 13, 2024
Inspira™ Secures a Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System
August 22, 2024
Inspira™ Technologies Announces FDA Listing and Market Readiness of New Product
August 13, 2024
Inspira™ Approached by Large Medical Company to Evaluate Operation of their Key Product with INSPIRA™ ART100 – Results Exceed 100% at Maximum Flow
For a one-on-one update on Inspira’s activities
Schedule a meeting with Joe Hayon, President and Co-founder
SEC Filings
Research Coverage
Firm
Analyst
E-mail
Aegis Capital
Nathan Weinstein, CFA
nweinstein@aegiscap.com
Inspira Technologies is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Inspira Technologies’ performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Inspira Technologies or its management. Inspira Technologies does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
